MelioBio wins the Golden Ticket

The programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases, rare blood and rare endocrine disorders. Candidates must show evidence of robust research plans and potential for successful development.

Established in 2024, Melio Bio focuses on development of novel inhibitors targeting GPR75, a genetically validated G protein-coupled receptor implicated in obesity and associated co-morbidities.

As Golden Ticket winner the company receives a one year rent-free incubation space at Pioneer’s Victoria House in London, access to Pioneer’s Venture Programmes, and annual Investment Showcase, plus support and mentoring from Pioneer and Novo Nordisk.